within Pharmacolibrary.Drugs.ATC.V;

model V03AB37
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.833333333333333e-07,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0089,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0035,
    k12             = 38,
    k21             = 38
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Idarucizumab</td></tr><tr><td>ATC code:</td><td>V03AB37</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran and is used as a reversal agent for the anticoagulant effects of dabigatran. It is approved for use in adult patients who require rapid reversal of dabigatran's anticoagulation due to emergency surgery, urgent procedures, or life-threatening or uncontrolled bleeding.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after single 5 g intravenous dose.</p><h4>References</h4><ol><li><p>Wang, Z, et al., &amp; Cui, Y (2020). Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. <i>Advances in therapy</i> 37(9) 3916â€“3928. DOI:<a href=\"https://doi.org/10.1007/s12325-020-01439-2\">10.1007/s12325-020-01439-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32691242/\">https://pubmed.ncbi.nlm.nih.gov/32691242</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end V03AB37;
